Literature DB >> 21374671

Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients.

Teerha Piratvisuth, Patrick Marcellin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21374671     DOI： 10.1002/hep.24136

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  7 in total

1.  Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?

Authors:  Monica A Konerman; Anna S Lok
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-23       Impact factor: 11.382

Review 2.  How to achieve immune control in chronic hepatitis B?

Authors:  Margo J H van Campenhout; Harry L A Janssen
Journal:  Hepatol Int       Date:  2014-09-06       Impact factor: 6.047

3.  Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients.

Authors:  Teerha Piratvisuth; Patrick Marcellin; Matei Popescu; Hans-Peter Kapprell; Vivien Rothe; Zhi-Meng Lu
Journal:  Hepatol Int       Date:  2011-06-24       Impact factor: 6.047

Review 4.  Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.

Authors:  Hong Peng; Fang Wei; Jun-Ying Liu; Huai-Dong Hu; Hong Ren; Peng Hu
Journal:  Hepatol Int       Date:  2015-07-11       Impact factor: 6.047

5.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Authors:  Yun-Fan Liaw; Jia-Horng Kao; Teerha Piratvisuth; Henry Lik Yuen Chan; Rong-Nan Chien; Chun-Jen Liu; Ed Gane; Stephen Locarnini; Seng-Gee Lim; Kwang-Hyub Han; Deepak Amarapurkar; Graham Cooksley; Wasim Jafri; Rosmawati Mohamed; Jin-Lin Hou; Wan-Long Chuang; Laurentius A Lesmana; Jose D Sollano; Dong-Jin Suh; Masao Omata
Journal:  Hepatol Int       Date:  2012-05-17       Impact factor: 6.047

6.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Authors:  S K Sarin; M Kumar; G K Lau; Z Abbas; H L Y Chan; C J Chen; D S Chen; H L Chen; P J Chen; R N Chien; A K Dokmeci; Ed Gane; J L Hou; W Jafri; J Jia; J H Kim; C L Lai; H C Lee; S G Lim; C J Liu; S Locarnini; M Al Mahtab; R Mohamed; M Omata; J Park; T Piratvisuth; B C Sharma; J Sollano; F S Wang; L Wei; M F Yuen; S S Zheng; J H Kao
Journal:  Hepatol Int       Date:  2015-11-13       Impact factor: 6.047

Review 7.  Clinical implications of HBsAg quantification in patients with chronic hepatitis B.

Authors:  Mauro Viganò; Pietro Lampertico
Journal:  Saudi J Gastroenterol       Date:  2012 Mar-Apr       Impact factor: 2.485
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.